CorMedix rises on US FDA approval for antimicrobial drug, smaller Q3 loss

CorMedix

15/11/2023 15:33

** Shares of CorMedix  CRMD.O  rise 33% to about a two-month
high of $4.15 in morning trade
    ** Biggest one-day pct. gain in nearly 3 years 
    ** Among the biggest pct. gainers on US stock exchange
    ** U.S. FDA approves DefenCath, co's antimicrobial drug that
reduces catheter-related bloodstream infections (CRBSIs) in
patients with kidney disease 
    ** The drug, DefenCath, will become the co's first
commercial drug 
    ** Late Tuesday, co posted a Q3 loss of 17 cents/shr,
narrower than Wall Street estimates of a loss of 22 cents/shr -
LSEG 
    ** Including session's gain, stock down 9.3% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))